[ad_1]
The “Endometriosis – Global Drug Forecast and Market Analysis to 2030” report has been added to ResearchAndMarkets.com’s offering.
The therapeutic market for endometriosis within the 7MM will grow from $1.061B in 2020 at a compound annual growth rate (CAGR) of 10.6% to $2.9B by 2030. In particular, the publisher expects the US market will contribute the most to the endometriosis market sales, accounting for roughly 68% of global sales in both 2020 ($730.65M) and 2030 ($577.1M).
The launch of GnRH antagonists relugolix and linzagolix across the 7MM will be the main drivers of growth during the forecast period. Other major drivers of growth include the launch of Quinagolide, the first endometriosis therapeutic that can treat pain without interfering with ovulation, and increased awareness of endometriosis, which leads to increased diagnosis rates.
The relugolix and linzagolix launch will provide the 5EU and Japanese markets with access to GnRH antagonists for the first time and should also bolster sales of AbbVie’s GnRH antagonist Orilissa (elagolix), which is available in the US. Given the novelty of the endometriosis pipeline paired With the decrease in use of existing endometriosis-specific therapeutics, the publisher expects the GnRH antagonist class to account for the majority of global sales by 2030.
The consensus among interviewed physicians regarding the current treatment landscape of endometriosis is that there are several unmet needs that have persisted for decades, and that current marketed therapies are insufficient in treating pain without significant side effects. Key Opinion Leaders (KOLs) interviewed by the publisher highlighted the importance of decreasing diagnosis delays, which can be improved by better diagnostic procedures.
KOLs also discussed the need for a therapeutic that can treat endometriosis-associated pain while not affecting the patient’s ability to conceive and treatments that can be used long-term.
Key Highlights
-
The endometriosis market is currently highly genericized and contains many off-label medications, such as oral contraceptives and NSAIDs, which provide affordable options with limited side effects. These factors create a stiff barrier …
Full story available on Benzinga.com
[ad_2]
Source link
